Kuros Biosciences has a Cash Ratio of 1.17. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Kuros Biosciences's Cash Ratio or its related term are showing as below:
XSWX:KURN'
s Cash Ratio Range Over the Past 10 Years
Min: 0.39 Med: 3.42 Max: 7.57
Current: 1.17
During the past 13 years, Kuros Biosciences's highest Cash Ratio was 7.57. The lowest was 0.39. And the median was 3.42.
XSWX:KURN's Cash Ratio is ranked better than 52.15% of 859
companies
in the Medical Devices & Instruments industry
Industry Median: 1.09
vs XSWX:KURN: 1.17
Kuros Biosciences Cash Ratio Historical Data
The historical data trend for Kuros Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kuros Biosciences's Cash Ratio
For the Medical Devices subindustry, Kuros Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Cash Ratio falls into.
Kuros Biosciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Kuros Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (XSWX:KURN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Kuros Biosciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Kuros Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:KURN has been successfully added to your 